# Severe Hereditary Hypofibrinogenemia in Pregnancy: A Case Report of a Novel Obstetrical Management with Thromboelastometry Guided Fibrinogen Supplementation

**Authors:** Grigorios Karampas, Konstantinos Karkalemis, Anastasia Bagiasta, Maria-Ekaterini Lefaki, Dimitra Metallinou, Chryssoula Staikou, Zoi Iliodromiti, Rozeta Sokou, Kassandra Tataropoulou, Theodora Boutsikou, Makarios Eleftheriades, Nikolaos Vlahos, Panagiotis Christopoulos, Marianna Politou

PMC · DOI: 10.3390/diagnostics15131671 · Diagnostics · 2025-06-30

## TL;DR

A novel approach using thromboelastometry guided fibrinogen supplementation successfully managed a pregnancy in a woman with severe hereditary hypofibrinogenemia.

## Contribution

This case introduces the use of ROTEM®-guided management for hereditary hypofibrinogenemia in pregnancy.

## Key findings

- ROTEM®-guided fibrinogen supplementation led to favorable maternal and neonatal outcomes.
- FIBTEM® and NATEM® assays provided individualized care and avoided unnecessary interventions.

## Abstract

Background and Clinical Significance: Hereditary Fibrinogen Disorders (HFDs) are a group of rare, inherited coagulation disorders with a wide spectrum of clinical presentations, ranging from asymptomatic cases to severe bleeding or thrombotic events. Among these, hereditary hypofibrinogenemia (HH) poses particular challenges in obstetric care due to its unpredictable course and limited evidence-based guidelines. Case Presentation: This case report describes the novel obstetrical management of a 37 years old multiparous woman with severe HH (SHH) guided not only by fibrinogen levels but also by rotational thromboelastometry (ROTEM®), a global test of hemostasis using specific parameters such as FIBTEM® and NATEM® assays. Despite persistent low fibrinogen levels during labor and peripartum (<100 mg/dL), favorable maternal and neonatal outcomes were achieved by relying on ROTEM®-based parameters to guide clinical decisions. Conclusions: Current recommendations for managing pregnancies in women with HFDs are largely based on expert consensus and exclusively use fibrinogen levels. This case supports the use of specific assays (FIBTEM® and NATEM®) of the ROTEM® global test of hemostasis as valuable tools in the obstetric management of women with HH. The use of FIBTEM® and NATEM® assays could provide individualized perinatal care, avoiding unnecessary therapeutic interventions and aiming for optimal perinatal outcomes.

## Linked entities

- **Proteins:** FGB (fibrinogen beta chain)

## Full-text entities

- **Genes:** FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}
- **Diseases:** HFDs (MESH:D009386), thrombotic (MESH:D013927), bleeding (MESH:D006470), inherited coagulation disorders (MESH:D025861)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12248511/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12248511/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12248511/full.md

---
Source: https://tomesphere.com/paper/PMC12248511